What is the difference between Semaglutide, Tirzepatide, and Retatrutide?

They differ by how many receptors they target. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. All three are studied in metabolic research and are sold for research use only.

Which is strongest in research?

These are research compounds, so strength is described in terms of receptor targets rather than human dosing. Retatrutide acts on three receptors, Tirzepatide on two, and Semaglutide on one. More targets does not automatically mean a better research outcome; it means a broader receptor profile studied in the literature.

Are these peptides interchangeable?

No. Each has a distinct receptor profile, molecular structure, and body of research. They are grouped together as the GLP-1 class in metabolic research but are studied as separate compounds.

GLP-1 · Metabolic · Research Use Only

Semaglutide vs Tirzepatide vs Retatrutide

Q: What does GLP-1 mean?

GLP-1 stands for glucagon-like peptide-1, a signaling molecule involved in metabolic pathways. A GLP-1 receptor agonist is a compound that activates that receptor. GIP and glucagon are additional receptors that the dual and triple agonists also act on.

These three are the most-studied members of the GLP-1 class of research peptides, and the difference between them is easier to grasp than it looks: it comes down to how many receptors each one targets. This guide compares them by mechanism and research focus, without making any human-use claims.

Research use only. This page compares research compounds by their studied receptor mechanisms. It is not medical advice, dosing guidance, or a claim about weight loss or treatment in humans. All products are sold strictly for research use and are not for human consumption.

The one-line difference

Semaglutide - a single agonist. It activates the GLP-1 receptor.
Tirzepatide - a dual agonist. It activates the GLP-1 and GIP receptors.
Retatrutide - a triple agonist. It activates the GLP-1, GIP, and glucagon receptors.

That progression, one receptor to two to three, is the core of the comparison. Each added receptor broadens the pathway profile studied in the research literature.

Side by side

Compound	Receptor targets	Class	Studied in research for
Semaglutide	GLP-1	Single agonist	Metabolic and glucose-regulation pathways
Tirzepatide	GLP-1 + GIP	Dual agonist	Metabolic pathways across two incretin receptors
Retatrutide	GLP-1 + GIP + glucagon	Triple agonist	Metabolic and energy-expenditure pathways across three receptors

What the receptors mean

GLP-1 (glucagon-like peptide-1) is a signaling molecule involved in metabolic and glucose-regulation pathways. A GLP-1 receptor agonist is a compound that activates that receptor. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin receptor that the dual and triple agonists also act on. Glucagon receptor activity is the third target that distinguishes Retatrutide. More targets does not automatically mean a better research result; it means a broader receptor profile being studied.

How to think about choosing one for research

Because these are research compounds, the comparison stays at the level of mechanism, not human dosing. Researchers generally select based on which receptor pathway a study is designed around: a single-receptor model points to Semaglutide, a two-receptor model to Tirzepatide, and a three-receptor model to Retatrutide. Each has its own molecular structure, stability profile, and literature. For handling, all three are lyophilized powders reconstituted the same way, so the reconstitution and storage steps are identical across them.

Frequently asked questions

What is the core difference?

Receptor count. Semaglutide targets GLP-1 alone, Tirzepatide targets GLP-1 and GIP, and Retatrutide targets GLP-1, GIP, and glucagon.

Which is strongest?

As research compounds they are described by receptor targets, not human potency. Retatrutide has the broadest profile with three receptors, but broader is not automatically better for a given study.

What does GLP-1 stand for?

Glucagon-like peptide-1, a signaling molecule involved in metabolic pathways. An agonist is a compound that activates its receptor.

Are they handled differently?

No. All three are lyophilized powders reconstituted with bacteriostatic water and refrigerated once in solution.

Related guides

GLP-1 research peptides in the catalog

Live inventory and exact pricing on Semaglutide, Tirzepatide, and Retatrutide research vials.

View catalog → Place an order →

Research Use Only. All products are sold strictly for laboratory and research purposes and are not for human consumption, medical, veterinary, or diagnostic use. Your Peptide Partner is not a compounding pharmacy under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act. These are investigational research compounds and are not approved products. This page is educational reference only - it is not medical advice or dosing guidance. By ordering you confirm you are a qualified purchaser and agree to our Terms & Conditions; all orders are subject to review and acceptance. See our Research Compliance policy.